Seeking Alpha

MannKind set for opening gap up

  • Shares of MannKind (MNKD) are up 19% premarket on healthy volume as investors get ready for the first full day of trading after the FDA announced its approval of Afrezza on Friday. Shares initially sold off but recovered a good bit of the down move. The closing price was $10.00 out of a range of $8.20 - 11.11 on turnover of 39.7M shares (4x normal volume).
Comments (12)
  • TruetoMNKD
    , contributor
    Comments (15) | Send Message
     
    Ding! And we are off to the races! GL! $12.42@07:11:38am est
    30 Jun 2014, 07:12 AM Reply Like
  • agatorcatcher
    , contributor
    Comments (7) | Send Message
     
    I think an overlooked market for Afrezza will be the criminal justice system - specifically detention facilities where syringes to treat inmates medical conditions is a very large problem. Inmates hide these syringes for a variety of not so desired uses and the authorities in charge would love to see their use greatly reduced. Just a thought that I haven't seen addressed and this is a worldwide problem.
    30 Jun 2014, 07:33 AM Reply Like
  • drew111
    , contributor
    Comments (485) | Send Message
     
    Good point! I work in corrections as a hobby (my real job is investing.) Your thoughts about this are spot on. Frankly, I'm somewhat embarrassed I did not think of that myself.
    30 Jun 2014, 08:04 AM Reply Like
  • Erbois
    , contributor
    Comments (224) | Send Message
     
    I work in corrections as a hobby (my real job is investing.)
    I wish I can buy you a pint for that!
    You really made me laugh a lot !
    30 Jun 2014, 08:10 AM Reply Like
  • drew111
    , contributor
    Comments (485) | Send Message
     
    Taddy Porter is one of favorites, though I'm a sucker for any good stout. Another hobby of mine... One I do not indulge in often enough.
    30 Jun 2014, 08:31 AM Reply Like
  • mrmcchumba2
    , contributor
    Comments (114) | Send Message
     
    There may actually be a little short squeeze. Yes, there is a large market cap, but Al owns half of it and he's not selling!!
    30 Jun 2014, 07:46 AM Reply Like
  • jcharchar
    , contributor
    Comment (1) | Send Message
     
    The shorts will get it in the shorts today. I do feel a little bad for them because they tried to make a little money (nothing wrong with that) but they did not realize how BIG Mannnkind is and will become very soon. Not only is this a big win for diabetes but that little inhaler is going to be a breakthrough device for many other drugs. Congratulations for the true longs that will continue to hold and benefit from all future Windfalls!
    30 Jun 2014, 07:56 AM Reply Like
  • Erbois
    , contributor
    Comments (224) | Send Message
     
    The shorts are only paying the tuition fees of what they learned from their Mentors, like Adam Frankenstein, the Mad Clown and their Gang Band!
    30 Jun 2014, 08:16 AM Reply Like
  • 916sp
    , contributor
    Comments (18) | Send Message
     
    Come on SA, just stating the facts w/o even a hint of a bash? You can do better!
    Happy covering, shorties!
    30 Jun 2014, 07:57 AM Reply Like
  • Patent News
    , contributor
    Comments (1391) | Send Message
     
    looks like it is still over priced with no partner, safety warnings and too many retail longs.
    30 Jun 2014, 09:02 AM Reply Like
  • tironakuqe
    , contributor
    Comment (1) | Send Message
     
    MNKD GOOOOOOOOOOOOOOOOOOOOOO
    30 Jun 2014, 09:08 AM Reply Like
  • JasonMiles
    , contributor
    Comments (168) | Send Message
     
    Once ADCOM happened in such a big way it should have been evident that this was headed in the right direction. It really makes me question the motivation and intelligence of some of these traders/investors who kept on shorting. There are some hurdles ahead but all signs for the future are pointing up for Mankind.
    30 Jun 2014, 10:01 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs